Received Apr 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
No additional adverse event (AE); Pharmacist reports 47 year old female received first dose of GARDASIL 9 on 3/24/2025; This spontaneous report was received from a Pharmacist on 21-Apr-2025 and refers to a 47-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 24-Mar-2025, the patient was vaccinated with first dose of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (GARDASIL) (strength, dose, route, lot # and expiration date were not reported) for prophylaxis (Product administered to patient of inappropriate age). No additional adverse event (AE). Lot # is being requested and will be submitted if received.